[Diagnostic performance of bone scintigraphy and (11)C-Choline PET/CT in the detection of bone metastases in patients with biochemical recurrence of prostate cancer]
- PMID: 25443648
- DOI: 10.1016/j.remn.2014.08.001
[Diagnostic performance of bone scintigraphy and (11)C-Choline PET/CT in the detection of bone metastases in patients with biochemical recurrence of prostate cancer]
Abstract
Aim: To compare bone scan (BS) with (11)C-Choline PET/CT for the detection of bone metastases in patients with biochemical recurrence of prostate cancer (PC).
Material and methods: A total of 169 patients with biochemical recurrence of PC(PSA:2.4-58 ng/ml) who were referred for both exams (0-15 days-in-between) were included. Lesion-detection-rate per patients and lesions were analyzed for both BS and (11)C-Choline PET/CT. Metastasis diagnosis was reached by: biopsy, CT/(18)F-Fluoride PET/MRI confirmation, or evidence of progression in subsequent imaging procedures.
Results: A total of 91 lesions were found to be active in BS and/or (11)C-choline PET/CT (40 patients), with 78 of which were metastatic. BS detected 38 blastic, 2 lytic and 10 non-CT-evident lesions. (11)C-Choline PET/CT detected 41 blastic, 4 lytic and 29 non-CT-evident lesions. BS and (11)C-Choline PET/CT sensitivities were 65.4% and 96.1%; specificities ere 38.5 and 92.3% (χ(2) 8.27, p<0.04). Both imaging techniques were negative in 118 patients. Tracer avid lesions were found in 51 patients: with 30/51 being BS and (11)C-Choline PET/CT concordant; in 21/51 patients had discordant lesions (kappa 0.712, p=0.00). Lesions were absolutely discordant in 10/19 patients,: 5 FN BS, 2 FP BS (degenerative changes; dysplasia), 1 FN (11)C-Choline PET/CT (blastic), 1 FP (11)C-Choline PET/CT (degenerative), 1 out of field-of-view lesion with (11)C-Choline PET/CT (tibia alone). (11)C-Choline PET/CT showed extraosseous involvement in 26/51 patients with bone metastases: 9 local recurrences, 5 infra-diaphragmatic-lymph-nodes, 2 supra-diaphragmatic, 5 local and infra-diaphragmatic, 4 infra- and supra-diaphragmatic, 1 supra-diaphragmatic and lung metastases.
Conclusion: (11)C-Choline PET/CT yielded better sensitivity and specificity than BS for the detection of bone involvement in patients with biochemical recurrence of PC and allowed extraosseous restaging, with an impact in the clinical management of these patients.
Keywords: (11)C-Choline PET/CT; (11)C-colina PET/TAC; Biochemical recurrence; Bone metastases; Bone scintigraphy; Cáncer de próstata; Gammagrafía ósea; Metástasis óseas; Prostate cancer; Recidiva bioquímica.
Copyright © 2014 Elsevier España, S.L.U. and SEMNIM. All rights reserved.
Similar articles
-
(11)C-choline PET/CT and multiparametric MRI in patients with biochemical relapse of prostate cancer.Actas Urol Esp. 2015 May;39(4):259-63. doi: 10.1016/j.acuro.2014.10.004. Epub 2014 Nov 15. Actas Urol Esp. 2015. PMID: 25454265 English, Spanish.
-
Role of 11C-choline PET/CT in the restaging of prostate cancer patients showing a single lesion on bone scintigraphy.Ann Nucl Med. 2010 Jul;24(6):485-92. doi: 10.1007/s12149-010-0390-x. Epub 2010 Jun 11. Ann Nucl Med. 2010. PMID: 20544323
-
Diagnostic utility and therapeutic impact of PET/CT [18F]F-Fluoromethylcholine -Choline in the biochemical recurrence of prostate cancer.Rev Esp Med Nucl Imagen Mol (Engl Ed). 2020 Sep-Oct;39(5):284-291. doi: 10.1016/j.remn.2020.03.010. Epub 2020 May 25. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2020. PMID: 32467000 English, Spanish.
-
A literature review of 18F-fluoride PET/CT and 18F-choline or 11C-choline PET/CT for detection of bone metastases in patients with prostate cancer.Nucl Med Commun. 2013 Oct;34(10):935-45. doi: 10.1097/MNM.0b013e328364918a. Nucl Med Commun. 2013. PMID: 23903557 Review.
-
Comparison of PSMA-PET/CT, choline-PET/CT, NaF-PET/CT, MRI, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a systematic review and meta-analysis.Skeletal Radiol. 2019 Dec;48(12):1915-1924. doi: 10.1007/s00256-019-03230-z. Epub 2019 May 24. Skeletal Radiol. 2019. PMID: 31127357
Cited by
-
Does whole-body bone SPECT/CT provide additional diagnostic information over [18F]-FCH PET/CT for the detection of bone metastases in the setting of prostate cancer biochemical recurrence?Cancer Imaging. 2020 Aug 12;20(1):58. doi: 10.1186/s40644-020-00333-y. Cancer Imaging. 2020. PMID: 32787923 Free PMC article.
-
Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons.Eur J Nucl Med Mol Imaging. 2016 Jul;43(8):1546-62. doi: 10.1007/s00259-016-3350-4. Epub 2016 Mar 9. Eur J Nucl Med Mol Imaging. 2016. PMID: 26956538 Review.
-
Quantitative bone SPECT/CT: high specificity for identification of prostate cancer bone metastases.BMC Musculoskelet Disord. 2019 Dec 26;20(1):619. doi: 10.1186/s12891-019-3001-6. BMC Musculoskelet Disord. 2019. PMID: 31878904 Free PMC article.
-
Diagnostic performance of choline PET/CT for the detection of bone metastasis in prostate cancer: A systematic review and meta-analysis.PLoS One. 2018 Sep 7;13(9):e0203400. doi: 10.1371/journal.pone.0203400. eCollection 2018. PLoS One. 2018. PMID: 30192819 Free PMC article.
-
68Ga-PSMA-PET/CT in comparison with 18F-fluoride-PET/CT and whole-body MRI for the detection of bone metastases in patients with prostate cancer: a prospective diagnostic accuracy study.Eur Radiol. 2019 Mar;29(3):1221-1230. doi: 10.1007/s00330-018-5682-x. Epub 2018 Aug 21. Eur Radiol. 2019. PMID: 30132104
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous